Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Oxford Nanopore's Breakout Rally: Is the DNA Sequencing Pioneer Finally Decoding Profitability?

Oxford Nanopore Technologies shares rose 8.02% today to 215.4p, a gain of 16p, according to the market data provided. The move values the group at around £1.95 billion and extends a powerful run that saw the shares close up more than 9% at 199.4p …

Divya Sood | 30 September 2026

Why is AstraZeneca (LSE:AZN) in focus after announcing a share investment in Summit Therapeutics?

In a regulatory announcement at 07:00 on 29 September 2026, AstraZeneca said it will invest $2bn in newly issued stock of Summit Therapeutics. The company will buy approximately 109 thousand shares of preferred stock, each convertible into Summit common stock at a 1:1,000 ratio.

Ankur Sharma | 30 September 2026

Oxford Nanopore Technologies Plc (LSE:ONT) Soars 9.5% to Fresh 52-Week High on Broker Upgrade, Patent Win and Insider Buying

LSE:ONT is one of the UK's most prominent life sciences technology companies. It develops nanopore-based sensing technology that can read DNA and RNA in real time, with applications across research, clinical diagnostics, biopharma, and applied markets such as food safety and infectious disease surveillance. …

Ankur Sharma | 30 September 2026

SkinBioTherapeutics Plc (LSE:SBTX) Shares Bounce 8.3% as Leadership Settles and Investors Reassess Skin Health Story

LSE:SBTX has faced a turbulent 2026. The life science company, which focuses on skin health and the gut-skin axis, saw its chief executive suspended and then resign in February amid a board investigation into his conduct. An independent investigation followed, and in April the …

Ankur Sharma | 30 September 2026

Why Is Shield Therapeutics Stock Rising as ACCRUFeR Growth Keeps Investors Watching? (LSE:STX)

• H1 2026Revenueincreased 42% to $30.4 million and the company remained on track for operating profitability during 2026.

Ankur Sharma | 30 September 2026

Convatec Group Plc (LSE:CTEC) Shares Climb 2.36% as Dividend Payday Nears and Defensive Healthcare Buying Returns

The move came on a day when theBlue-Chipindexfell 0.45%, pressured by soaring US bond yields and weaker energy stocks. Against that uncertain backdrop, investors gravitated toward defensive names with steady,Recurring Revenuestreams, and LSE:CTEC fitted that profile well.

Ankur Sharma | 30 September 2026

Solvonis Therapeutics (LSE:SVNS) reanalysis shows 67% cut in heavy drinking days for SVN-001

On 29 September 2026 Solvonis Therapeutics plc (LSE:SVNS) released new analyses of data from KARE, a randomised Phase 2 trial of adjunctive ketamine in alcohol use disorder (AUD) led by Professor Celia Morgan at the University of Exeter. Solvonis uses the trial data for …

Ankur Sharma | 30 September 2026

Thalia Therapeutics (LSE:THAT) secures Chinese patent for miRisten in AML

On 29 September 2026 Thalia Therapeutics plc (LSE:THAT) said a new patent had been granted in China for miRisten (THAT-001), an anti-microRNA-126 therapeutic being developed initially for patients with acute myeloid leukaemia (AML), which the company describes as an aggressive blood cancer with significant …

Ankur Sharma | 30 September 2026

Abingdon Health (LSE:ABDX) wins UKAS ISO/IEC 17025 accreditation for Doncaster lab

On 29 September 2026 Abingdon Health plc (LSE:ABDX) said that Abingdon Analytical Ltd, the group's performance evaluation laboratory based in Doncaster, UK, had been granted accreditation to ISO/IEC 17025:2017 by the United Kingdom Accreditation Service (UKAS).

Ankur Sharma | 30 September 2026

Why Did Oxford Nanopore Technologies (LSE:ONT) Rise 9.26% as Genomics Demand Returned to Focus?

Oxford Nanopore Technologies gained 9.26% on 29 September, extending a strong late-September trading pattern. The company remains closely watched because its long-read sequencing technology addresses applications across genomics, clinical research, infectious disease surveillance and life-science research.

Ankur Sharma | 30 September 2026
Support

Hi! How can we help you today?

Loading…